Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia

Rael D. Strous, Raya Lapidus, Dina Viglin, Moshe Kotler, Herbert M. Lachman

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Based on their metabolic inactivation of dopamine and norepinephrine, genes encoding the catechol-O-methyltransferase (COMT) enzyme are appropriate candidates to consider in the pathogenesis of schizophrenia. COMT enzyme activity is regulated by a common polymorphism causing substantial variations in enzymatic activity, and evidence for allelic or genotypic association with cognitive and behavioral features of schizophrenia has been noted. Since the role of COMT in schizophrenia remains inconclusive, we determined whether any association exists between COMT genotypes and clinical symptomatology in a large cohort of schizophrenia subjects. DNA was extracted from peripheral blood in 111 patients with DSM-IV criteria schizophrenia (77 M, 34 F) and genotyped for COMT polymorphisms. Subjects were also were rated by means of the PANSS and the CGI. No association was found between COMT genotype or allele frequency and gender. No associations were observed between COMT and CGI or PANSS scores. Our findings do not support hypotheses regarding associations between COMT polymorphisms and clinical state in schizophrenia, contrary to other studies suggesting involvement of the COMT polymorphism with schizophrenia phenotype. Thus, while speculative, it may be suggested that a modifying gene may be required in order for the COMT polymorphism to manifest at the clinical level in schizophrenia with one set of susceptibility genes being more sensitive to COMT enzyme variability than others.

Original languageEnglish (US)
Pages (from-to)170-173
Number of pages4
JournalNeuroscience Letters
Volume393
Issue number2-3
DOIs
StatePublished - Jan 30 2006

Fingerprint

Catechol O-Methyltransferase
Schizophrenia
Enzymes
Genotype
Genes
Gene Frequency
Diagnostic and Statistical Manual of Mental Disorders
Dopamine
Norepinephrine

Keywords

  • COMT
  • Polymorphism
  • Schizophrenia

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia. / Strous, Rael D.; Lapidus, Raya; Viglin, Dina; Kotler, Moshe; Lachman, Herbert M.

In: Neuroscience Letters, Vol. 393, No. 2-3, 30.01.2006, p. 170-173.

Research output: Contribution to journalArticle

Strous, Rael D. ; Lapidus, Raya ; Viglin, Dina ; Kotler, Moshe ; Lachman, Herbert M. / Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia. In: Neuroscience Letters. 2006 ; Vol. 393, No. 2-3. pp. 170-173.
@article{a1849d74e3344fceafa35406dcfc044e,
title = "Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia",
abstract = "Based on their metabolic inactivation of dopamine and norepinephrine, genes encoding the catechol-O-methyltransferase (COMT) enzyme are appropriate candidates to consider in the pathogenesis of schizophrenia. COMT enzyme activity is regulated by a common polymorphism causing substantial variations in enzymatic activity, and evidence for allelic or genotypic association with cognitive and behavioral features of schizophrenia has been noted. Since the role of COMT in schizophrenia remains inconclusive, we determined whether any association exists between COMT genotypes and clinical symptomatology in a large cohort of schizophrenia subjects. DNA was extracted from peripheral blood in 111 patients with DSM-IV criteria schizophrenia (77 M, 34 F) and genotyped for COMT polymorphisms. Subjects were also were rated by means of the PANSS and the CGI. No association was found between COMT genotype or allele frequency and gender. No associations were observed between COMT and CGI or PANSS scores. Our findings do not support hypotheses regarding associations between COMT polymorphisms and clinical state in schizophrenia, contrary to other studies suggesting involvement of the COMT polymorphism with schizophrenia phenotype. Thus, while speculative, it may be suggested that a modifying gene may be required in order for the COMT polymorphism to manifest at the clinical level in schizophrenia with one set of susceptibility genes being more sensitive to COMT enzyme variability than others.",
keywords = "COMT, Polymorphism, Schizophrenia",
author = "Strous, {Rael D.} and Raya Lapidus and Dina Viglin and Moshe Kotler and Lachman, {Herbert M.}",
year = "2006",
month = "1",
day = "30",
doi = "10.1016/j.neulet.2005.09.067",
language = "English (US)",
volume = "393",
pages = "170--173",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "2-3",

}

TY - JOUR

T1 - Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia

AU - Strous, Rael D.

AU - Lapidus, Raya

AU - Viglin, Dina

AU - Kotler, Moshe

AU - Lachman, Herbert M.

PY - 2006/1/30

Y1 - 2006/1/30

N2 - Based on their metabolic inactivation of dopamine and norepinephrine, genes encoding the catechol-O-methyltransferase (COMT) enzyme are appropriate candidates to consider in the pathogenesis of schizophrenia. COMT enzyme activity is regulated by a common polymorphism causing substantial variations in enzymatic activity, and evidence for allelic or genotypic association with cognitive and behavioral features of schizophrenia has been noted. Since the role of COMT in schizophrenia remains inconclusive, we determined whether any association exists between COMT genotypes and clinical symptomatology in a large cohort of schizophrenia subjects. DNA was extracted from peripheral blood in 111 patients with DSM-IV criteria schizophrenia (77 M, 34 F) and genotyped for COMT polymorphisms. Subjects were also were rated by means of the PANSS and the CGI. No association was found between COMT genotype or allele frequency and gender. No associations were observed between COMT and CGI or PANSS scores. Our findings do not support hypotheses regarding associations between COMT polymorphisms and clinical state in schizophrenia, contrary to other studies suggesting involvement of the COMT polymorphism with schizophrenia phenotype. Thus, while speculative, it may be suggested that a modifying gene may be required in order for the COMT polymorphism to manifest at the clinical level in schizophrenia with one set of susceptibility genes being more sensitive to COMT enzyme variability than others.

AB - Based on their metabolic inactivation of dopamine and norepinephrine, genes encoding the catechol-O-methyltransferase (COMT) enzyme are appropriate candidates to consider in the pathogenesis of schizophrenia. COMT enzyme activity is regulated by a common polymorphism causing substantial variations in enzymatic activity, and evidence for allelic or genotypic association with cognitive and behavioral features of schizophrenia has been noted. Since the role of COMT in schizophrenia remains inconclusive, we determined whether any association exists between COMT genotypes and clinical symptomatology in a large cohort of schizophrenia subjects. DNA was extracted from peripheral blood in 111 patients with DSM-IV criteria schizophrenia (77 M, 34 F) and genotyped for COMT polymorphisms. Subjects were also were rated by means of the PANSS and the CGI. No association was found between COMT genotype or allele frequency and gender. No associations were observed between COMT and CGI or PANSS scores. Our findings do not support hypotheses regarding associations between COMT polymorphisms and clinical state in schizophrenia, contrary to other studies suggesting involvement of the COMT polymorphism with schizophrenia phenotype. Thus, while speculative, it may be suggested that a modifying gene may be required in order for the COMT polymorphism to manifest at the clinical level in schizophrenia with one set of susceptibility genes being more sensitive to COMT enzyme variability than others.

KW - COMT

KW - Polymorphism

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=29244470822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29244470822&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2005.09.067

DO - 10.1016/j.neulet.2005.09.067

M3 - Article

VL - 393

SP - 170

EP - 173

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2-3

ER -